Valsartan
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318970

CAS#: 137862-53-4

Description: Valsartan is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor. Valsartan is mainly used for treatment of high blood pressure, congestive heart failure, and to increase the chances of living longer after a heart attack. Valsartan is used to treat high blood pressure, congestive heart failure, and to reduce death for people with left ventricular dysfunction after having had a heart attack.


Price and Availability

Size
Price

1g
USD 150
10g
USD 650
100g
USD 1650
Size
Price

2g
USD 250
20g
USD 850
200g
USD 1950
Size
Price

5g
USD 450
50g
USD 1250
500g
USD 3650

Valsartan, purity > 98%, is in stock. The same day shipping out after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Note: the estimated shipping out time for order > 100 g may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318970
Name: Valsartan
CAS#: 137862-53-4
Chemical Formula: C24H29N5O3
Exact Mass: 435.22704
Molecular Weight: 435.528
Elemental Analysis: C, 66.19; H, 6.71; N, 16.08; O, 11.02


Synonym: CGP48933, CGP-48933, CGP 48933, Valsartan, Diovan, Miten, Nisis, Prova, Tareg, Vals, Walsartan

IUPAC/Chemical Name: (S)-3-methyl-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoic acid

InChi Key: ACWBQPMHZXGDFX-QFIPXVFZSA-N

InChi Code: InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

SMILES Code: CC(C)[C@H](N(CC1=CC=C(C2=CC=CC=C2C3=NNN=N3)C=C1)C(CCCC)=O)C(O)=O


Technical Data

Appearance:
White to off-white crystalline powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Lillyblad MP. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14. Review. PubMed PMID: 26175499.

2: Ardiana F, Suciati, Indrayanto G. Valsartan. Profiles Drug Subst Excip Relat Methodol. 2015;40:431-93. doi: 10.1016/bs.podrm.2015.01.004. Epub 2015 Mar 21. Review. PubMed PMID: 26051690.

3: Janić M, Lunder M, Šabovič M. A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age. Biomed Res Int. 2015;2015:235709. doi: 10.1155/2015/235709. Epub 2015 Mar 3. Review. PubMed PMID: 25821790; PubMed Central PMCID: PMC4363554.

4: Sander GE, Giles TD. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension. Expert Opin Pharmacother. 2015 Apr;16(5):763-70. doi: 10.1517/14656566.2015.1020790. Review. PubMed PMID: 25747524.

5: Güleç S. Valsartan after myocardial infarction. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S9-13. doi: 10.5152/akd.2014.00002. Review. PubMed PMID: 25604205.

6: Kızılırmak P, Üresin AY. Hypertension and valsartan. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S20-4. doi: 10.5152/akd.2014.00004. Review. PubMed PMID: 25604204.

7: Ecder T. Renal and metabolic effects of valsartan. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S14-9. doi: 10.5152/akd.2014.00003. Review. PubMed PMID: 25604203.

8: Kılıçkıran Avcı B, İkitimur B, Karadağ B, Öngen Z. Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S1-8. doi: 10.5152/akd.2014.00001. Review. PubMed PMID: 25604202.

9: Varagic J, Punzi H, Ferrario CM. Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. Integr Blood Press Control. 2014 Nov 26;7:61-70. doi: 10.2147/IBPC.S50954. eCollection 2014. Review. PubMed PMID: 25473311; PubMed Central PMCID: PMC4251532.

10: Lawrence Gould A, Unniachan S, Wu D. Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control. Int J Clin Pract. 2014 Feb;68(2):163-72. doi: 10.1111/ijcp.12343. Review. PubMed PMID: 24460615.

11: Huang QF, Li Y, Wang JG. Overview of clinical use and side effect profile of valsartan in Chinese hypertensive patients. Drug Des Devel Ther. 2013 Dec 30;8:79-86. doi: 10.2147/DDDT.S38617. Review. PubMed PMID: 24403822; PubMed Central PMCID: PMC3883632.

12: Ferdinand KC, Nasser SA. A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension. Am J Cardiovasc Drugs. 2013 Oct;13(5):301-13. doi: 10.1007/s40256-013-0033-4. Review. PubMed PMID: 23784267; PubMed Central PMCID: PMC3781303.

13: Voors AA, Dorhout B, van der Meer P. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7. doi: 10.1517/13543784.2013.797963. Epub 2013 May 10. Review. PubMed PMID: 23663006.

14: Volpe M. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. Expert Rev Cardiovasc Ther. 2012 Aug;10(8):1061-72. doi: 10.1586/erc.12.80. Review. PubMed PMID: 23030295.

15: Benge CD, Muldowney JA 3rd. The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population. Expert Opin Drug Metab Toxicol. 2012 Nov;8(11):1469-82. doi: 10.1517/17425255.2012.725721. Epub 2012 Sep 24. Review. PubMed PMID: 22998368.

16: Lacourcière Y. Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review. Clin Exp Hypertens. 2013;35(1):50-60. doi: 10.3109/10641963.2012.690468. Epub 2012 Aug 6. Review. PubMed PMID: 22866964.

17: Miura S, Saku K. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine. J Int Med Res. 2012;40(1):1-9. Review. PubMed PMID: 22429340.

18: Sestito A. Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan. Eur Rev Med Pharmacol Sci. 2011 Nov;15(11):1247-55. Review. PubMed PMID: 22195356.

19: Maksimov ML, Mochkin IA, Starodubtsev AK. [Application of AT1-angiotensin II receptor blocker valsartan in clinical practice]. Kardiologiia. 2011;51(8):77-84. Review. Russian. PubMed PMID: 21942964.

20: Bains J, Smith WB. Valsartan plus hydrochlorothiazide: a review of its use since its introduction. Expert Opin Pharmacother. 2011 Aug;12(12):1975-84. doi: 10.1517/14656566.2011.587124. Epub 2011 Jul 6. Review. PubMed PMID: 21728903.